 |
  
Biotech Jobs, Learning Resources, Career Tools
|
|
| ||||||||||||||||||||||||||||||
|  |  Curis to Present at CIBC World Markets 16th Annual Healthcare ConferencePress Release November 3, 2005 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 3, 2005 - Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that the Company will be presenting at the CIBC World Markets 16th Annua l Healthcare Conference 2005 on Wednesday, November 9th, at the Waldorf-Astoria in New York City. Daniel Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of Curis' business and collaborations at 10:00 a.m. Eastern. There will be a webcast of the presentation at: http://conferences.cibcwm.com/health05/ Webcast source code: november The presentation will be archived shortly after the live event and available for 30 days following the conference. The presentation will also be available on the Investor Relations section of Curis' website at www.curis.com. About Curis, Inc. Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under two collaborations with Genentech, one of which includes a co-development arrangement for a basal cell carcinoma product candidate that is currently in Phase I clinical trials), neurological disorders (under collaboration with Wyeth), hair growth (under collaboration with Procter & Gamble), kidney and other diseases (licensed to Ortho Biotech Products and under development at Centocor, both subsidiaries of Johnson & Johnson), and cardiovascular disease. Curis also possesses robust small molecule drug screening technologies and preclinical scientific expertise that Curis believes it can use to create a sustainable drug candidate pipeline including, for example, its efforts in Spinal Muscular Atrophy (under sponsored research agreement with the Spinal Muscular Atrophy Foundation). For more information, please visit the Curis web site at www.curis.com. Contact Curis, Inc. Michael P. Gray, 617-503-6632 Chief Financial Officer or Megan E. Burling, 617-503-6658 Director, Corporate Communications
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
 |
|
 |
Print
This Page